NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- NCT02846623 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on NCT02846623 (atezolizumab plus obinutuzumab plus venetoclax in chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter syndrome) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02846623 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Small Lymphocytic Lymphoma
- Interventions
- Atezolizumab; Laboratory Biomarker Analysis; Obinutuzumab; Venetoclax
- Arms
- Cohort I (obinutuzumab, atezolizumab, venetoclax) · Experimental
- Cohort II (obinutuzumab, atezolizumab, venetoclax) · Experimental
- Enrollment
- 50
- Primary outcomes
- Minimal residual disease (MRD) negative rate (Cohort I)
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- Jan 31, 2017
- Primary completion
- Feb 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02846623 · updated Aug 10, 2026